Qiagen N.V.

Symbol: QIA.DE

XETRA

40.345

EUR

Market price today

  • 28.6355

    P/E Ratio

  • 0.1009

    PEG Ratio

  • 8.93B

    MRK Cap

  • 0.06%

    DIV Yield

Qiagen N.V. (QIA-DE) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.63%

Operating Profit Margin

0.21%

Net Profit Margin

0.17%

Return on Assets

0.06%

Return on Equity

0.09%

Return on Capital Employed

0.09%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO:Mr. Thierry Bernard
Full-time employees:5900
City:Venlo
Address:Hulsterweg 82
IPO:1998-07-22
CIK:

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

General Outlook

When we look at how much money they make before expenses, they keep 0.628% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.211%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.174%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.058% return, is a testament to Qiagen N.V.'s adeptness in optimizing resource deployment. Qiagen N.V.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.092%. Furthermore, the proficiency of Qiagen N.V. in capital utilization is underscored by a remarkable 0.085% return on capital employed.

Stock Prices

Qiagen N.V.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $39.85, while its low point bottomed out at $39.38. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Qiagen N.V.'s stock market.

Liquidity Ratios

Analyzing QIA.DE liquidity ratios reveals its financial health of the firm. The current ratio of 184.43% gauges short-term asset coverage for liabilities. The quick ratio (120.67%) assesses immediate liquidity, while the cash ratio (50.11%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio184.43%
Quick Ratio120.67%
Cash Ratio50.11%

Profitability Ratios

QIA.DE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 21.83% underscores its earnings before tax deductions. The effective tax rate stands at 20.40%, revealing its tax efficiency. The net income per EBT, 79.60%, and the EBT per EBIT, 103.71%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 21.05%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin21.83%
Effective Tax Rate20.40%
Net Income per EBT79.60%
EBT per EBIT103.71%
EBIT per Revenue21.05%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.84, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 563.76% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding121
Days of Inventory Outstanding203
Operating Cycle267.98
Days of Payables Outstanding38
Cash Conversion Cycle230
Receivables Turnover5.64
Payables Turnover9.58
Inventory Turnover1.80
Fixed Asset Turnover2.54
Asset Turnover0.33

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 2.35, and free cash flow per share, 1.61, depict cash generation on a per-share basis. The cash per share value, 4.03, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.27, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share2.35
Free Cash Flow per Share1.61
Cash per Share4.03
Operating Cash Flow Sales Ratio0.27
Free Cash Flow to Operating Cash Flow Ratio0.69
Cash Flow Coverage Ratio0.35
Short Term Coverage Ratio0.88
Capital Expenditure Coverage Ratio3.20
Dividend Paid and Capex Coverage Ratio3.20

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 25.89%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.42, we discern the balance between debt and equity financing. The long-term debt to capitalization, 20.23%, and total debt to capitalization, 29.46%, ratios shed light on its capital structure. An interest coverage of 8.29 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio25.89%
Debt Equity Ratio0.42
Long Term Debt to Capitalization20.23%
Total Debt to Capitalization29.46%
Interest Coverage8.29
Cash Flow to Debt Ratio0.35
Company Equity Multiplier1.61

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 8.88, provides a glimpse into top-line earnings distributed across each share. Net income per share, 1.54, reflects the portion of profit attributed to each share. The book value per share, 17.21, represents the net asset value distributed per share, while the tangible book value per share, 3.64, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share8.88
Net Income Per Share1.54
Book Value Per Share17.21
Tangible Book Value Per Share3.64
Shareholders Equity Per Share17.21
Interest Debt Per Share7.16
Capex Per Share-0.74

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -8.23%, indicates top-line expansion, while the gross profit growth, -10.90%, reveals profitability trends. EBIT growth, -22.87%, and operating income growth, -22.87%, offer insights into operational profitability progression. The net income growth, -19.35%, showcases bottom-line expansion, and the EPS growth, -17.20%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-8.23%
Gross Profit Growth-10.90%
EBIT Growth-22.87%
Operating Income Growth-22.87%
Net Income Growth-19.35%
EPS Growth-17.20%
EPS Diluted Growth-15.38%
Weighted Average Shares Growth0.25%
Weighted Average Shares Diluted Growth-4.63%
Operating Cash Flow Growth-35.76%
Free Cash Flow Growth-47.58%
10-Year Revenue Growth per Share53.70%
5-Year Revenue Growth per Share34.02%
3-Year Revenue Growth per Share11.21%
10-Year Operating CF Growth per Share80.66%
5-Year Operating CF Growth per Share30.89%
3-Year Operating CF Growth per Share-1.22%
10-Year Net Income Growth per Share403.12%
5-Year Net Income Growth per Share83.60%
3-Year Net Income Growth per Share390.52%
10-Year Shareholders Equity Growth per Share42.84%
5-Year Shareholders Equity Growth per Share47.99%
3-Year Shareholders Equity Growth per Share62.30%
Receivables Growth59.27%
Inventory Growth11.29%
Asset Growth-2.74%
Book Value per Share Growth9.57%
Debt Growth-17.70%
R&D Expense Growth4.56%
SGA Expenses Growth-4.10%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 10,863,414,472.722, captures the company's total value, considering both debt and equity. Income quality, 1.35, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.06, gauges operational efficiency, while the research and development to revenue, 10.10%, highlights investment in innovation. The ratio of intangibles to total assets, 49.10%, indicates the value of non-physical assets, and capex to operating cash flow, -35.43%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value10,863,414,472.722
Income Quality1.35
Sales General and Administrative to Revenue0.06
Research and Development to Revenue10.10%
Intangibles to Total Assets49.10%
Capex to Operating Cash Flow-35.43%
Capex to Revenue-8.28%
Capex to Depreciation-79.29%
Stock-Based Compensation to Revenue2.40%
Graham Number24.43
Return on Tangible Assets10.97%
Graham Net Net-3.00
Working Capital1,068,267,000
Tangible Asset Value805,211,000
Net Current Asset Value-159,866,000
Average Receivables419,696,500
Average Payables91,444,500
Average Inventory378,172,500
Days Sales Outstanding96
Days Payables Outstanding42
Days of Inventory On Hand199
ROIC6.10%
ROE0.09%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.68, and the price to book ratio, 2.68, reflect the market's valuation relative to the company's book value. The price to sales ratio, 4.97, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 26.90, and price to operating cash flows, 18.53, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.68
Price to Book Ratio2.68
Price to Sales Ratio4.97
Price Cash Flow Ratio18.53
Price Earnings to Growth Ratio0.10
Enterprise Value Multiple12.11
Price Fair Value2.68
Price to Operating Cash Flow Ratio18.53
Price to Free Cash Flows Ratio26.90
Price to Tangible Book Ratio2.63
Enterprise Value to Sales5.53
Enterprise Value Over EBITDA15.01
EV to Operating Cash Flow23.64
Earnings Yield3.41%
Free Cash Flow Yield2.97%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Qiagen N.V. (QIA.DE) on the XETRA in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 28.635 in 2024.

What is the ticker symbol of Qiagen N.V. stock?

The ticker symbol of Qiagen N.V. stock is QIA.DE.

What is company IPO date?

IPO date of Qiagen N.V. is 1998-07-22.

What is company current share price?

Current share price is 40.345 EUR.

What is stock market cap today?

The market cap of stock today is 8930648165.000.

What is PEG ratio in 2024?

The current 0.101 is 0.101 in 2024.

What is the number of employees in 2024?

In 2024 the company has 5900.